10 pharmaceutical sub-leaders are bullish, future or out of the bull stocks

Pharmaceutical Network Pharmaceutical Stock MarketThe pharmaceutical industry is an important part of the national economyAccording to IQVIA, global drug spending in 2019 was close to $1.3 trillion, making China the world's second-largest pharmaceutical market, and global drug spending is expected to exceed $1.5 trillion by 2023At present, China's pharmaceutical industry is in a period of high-speed growth, with the aging of the population, urbanization level is constantly improving, medical security system gradually improved, people's demand for drugs continues to expand, China's pharmaceutical industry as a whole will show a sustained trend of good developmentthis year, the pharmaceutical sector has also become the focus of investor scare and institutional researchThe pharmaceutical sector has always been an important target through the bull bear, but also the bull stock concentration camp, in the medium and long term, the selection of undervaluation of good pharmaceutical stocks is the most important, with the intensification of the structure of medicine, the leading enterprises in the sub-sector will undoubtedly be more concernedSo, what segment sausers are favored?Innovation drug leader - Hengrui Pharmaceutical
innovation drug sector has long been favored by investorsHengrui Pharma has a strong innovation strength, in the pharmaceutical and biological industry 2020 ASCO conference, Hengrui Pharmaceutical's Apatini, Prigatini, CarreyZumai single anti-three heavy-duty innovative drugs published a number of dataAmong them, the data on the treatment of liver cancer on the apatine single drug 2 line is similar to that of other international drug companies, the results of pibutinib continue to show excellent clinical data on HER2-positive breast cancer, and the Carellizumab has published several data combined with other drugs, highlighting the drug's status as a "cornerstone" anti-tumor drugClinical CRO leader - Tiger Pharmaceuticalsdomestic CRO industry is in a high-speed development stage, leading enterprises are prominent advantagesTiger Pharma is China's leading provider of integrated biopharmaceutical research and development services, and its global reach is expandingAccording to Frost Sullivan, Tiger Pharma is China's top clinical contract research institution, based on revenue in 2019 and the number of clinical trials under way by the end of 2019 In terms of 2019 revenue, Tag Pharma is also in the top 10 of the world's clinical contract research institutions, and Zhang Lei's management of GaoQi Capital is also a shareholder of Tiger Pharma Vaccine leader - Zhifei Bio, Kantai Bio
With the public's awareness of disease prevention further enhanced, high-priced class II seedlings will be gradually accepted, and the industry's regulatory efforts continue to tighten, with the ability of vaccine research and development enterprises will further enjoy performance and valuation improvement, research and development strength, there are heavy products in research or listed vaccine enterprises such as Zhifei Bio, Kantai Bio or benefit Blood products leader - Hualan biological blood products industry threshold is very high, the current domestic top five blood products enterprise market share of more than 70%, due to national requirements can not prepare more than 6 kinds of blood products enterprises can not add pulping station, so the future pulping station will further close to the leader Hualan Bio's 2019 operating income of 3.7 billion yuan, outperforming all listed enterprises in the same industry The industry believes that Hualan Bio's future development space is still huge, because of the huge financing capacity and management vision and ambition The nuclear medicine leader - Dongcheng Pharmaceutical the domestic nuclear medicine market is booming, Dongcheng Pharmaceutical nuclide drugs steady growth, nuclear pharmacy national distribution continues to advance In 2019, the company's nuclide drug revenue was RMB1,062 million, up 22.02% YoY In 2019, the company added Liuzhou, Liaocheng, Shijiazhuang, Guangzhou four nuclear drug centers, the number of nuclear pharmacies reached 13, 15 are under construction, the future will be added 5-6 nuclear drug centers each year, the company is expected to put into operation in the next three years will be more than 30 nuclear drug centers, to achieve a national distribution of nuclear pharmacies Pharmaceutical wholesale leader - Shanghai Pharmaceutical in the pharmaceutical wholesale sector, with volume procurement advance payment system to bring significant opportunities for the improvement of cash flow, the industry believes that with the advantages of quality regulation distribution, upstream and downstream industrial chain layout more perfect enterprises are expected to stand out, industrial and commercial integration leader Shanghai Pharmaceutical is optimistic Modern Chinese medicine leader - Tianshili In recent years, the Chinese medicine industry continues to develop, especially in this year's relevant favorable policies, the industry will benefit in the long term The industry expects that by 2020, China's large-scale health industry of Chinese medicine is expected to exceed 3 trillion, the size of the industry is expected to maintain a compound growth rate of 20% Leading company Tianshili is expected to benefit from this Multi-product line medical equipment - Murray Medical the future, with a broad market space for the field of medical device import substitution will accelerate As a leading domestic equipment, Murray Medical is committed to relying on technological innovation to achieve high-end market breakthroughs Data show that in the past three years, Myer Medical's research and development investment ratio reached an average of 10.14 percent, this proportion of investment, even surpassthe overseas medical device leading enterprises At present, the company has established a research and development innovation platform based on global resource allocation, in Shenzhen, Nanjing, Beijing, Xi'an, Chengdu, Silicon Valley, New Jersey and Seattle, USA, the united States set up eight research and development centers, and in December 2019, opened the ninth research and development center - Wuhan Research Institute project construction Home medical device leader - Fish Leap Medical China's medical device industry has entered a dividend period, especially in the family medical device and other fields of the industry prospects are very broad Fish Leap medical home medical equipment leading position is basically established, the company's products include not only respiratory oxygen supply, blood pressure and other household medical equipment, but also disinfection control, medical first aid, surgical instruments, Chinese medicine equipment, eye equipment, rehabilitation care and other medical clinical related products Pharmacy leader - Yifeng pharmacy with zero-plus, two-vote system, with the volume of procurement, as well as drugstore classification management and other policies to accelerate, small and medium-sized pharmacies survival pressure is very great, and large drugstore chains will have an impact, but relatively controllable From the beginning of the year to the end of March, Yifeng Pharmacy far outperformed the broader market and many blue-chip stocks Not only that, but the stock has risen more than 920 per cent in five years since it went public in February 2015, which the industry considers the right bull stock.